ProQR Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de ProQR Therapeutics es Daniel de Boer , nombrado en Feb 2012, tiene una permanencia de 12.75 años. compensación anual total es €2.44M, compuesta por 21.5% salario y 78.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.68% de las acciones de la empresa, por valor de $2.55M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 6.2 años, respectivamente.
Información clave
Daniel de Boer
Chief Executive Officer (CEO)
€2.4m
Compensación total
| Porcentaje del salario del CEO | 21.5% |
| Permanencia del CEO | 12.8yrs |
| Participación del CEO | 0.7% |
| Permanencia media de la dirección | 4.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.2yrs |
Actualizaciones recientes de la dirección
Recent updates
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -€24m |
| Jun 30 2024 | n/a | n/a | -€22m |
| Mar 31 2024 | n/a | n/a | -€27m |
| Dec 31 2023 | €2m | €524k | -€28m |
| Sep 30 2023 | n/a | n/a | -€36m |
| Jun 30 2023 | n/a | n/a | -€54m |
| Mar 31 2023 | n/a | n/a | -€59m |
| Dec 31 2022 | €2m | €504k | -€64m |
| Sep 30 2022 | n/a | n/a | -€69m |
| Jun 30 2022 | n/a | n/a | -€61m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€61m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
| Sep 30 2018 | n/a | n/a | -€35m |
| Jun 30 2018 | n/a | n/a | -€40m |
| Mar 31 2018 | n/a | n/a | -€44m |
| Dec 31 2017 | €1m | €353k | -€44m |
Compensación vs. Mercado: La compensación total ($USD2.54M) de Daniel está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.18M).
Compensación vs. Ingresos: La compensación de Daniel ha sido consistente con los resultados de la empresa en el último año.
CEO
Daniel de Boer (41 yo)
12.8yrs
Permanencia
€2,439,000
Compensación
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 12.8yrs | €2.44m | 0.68% $ 2.5m | |
| Founder & Independent Member of Supervisory Board | no data | €150.00k | 0.41% $ 1.5m | |
| Chief Corporate Development Officer | 2.4yrs | €1.31m | 0.45% $ 1.7m | |
| Co-Founder | 12.8yrs | €34.00k | sin datos | |
| Chief Financial Officer | 2yrs | sin datos | sin datos | |
| Chief People & Operations Officer | 4.8yrs | sin datos | sin datos | |
| Vice President of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Junior Financial Controller | no data | sin datos | sin datos |
4.8yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PRQR se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Independent Member of Supervisory Board | 10.8yrs | €150.00k | 0.41% $ 1.5m | |
| Independent Member of Supervisory Board | 10.2yrs | €126.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.4yrs | sin datos | sin datos | |
| Supervisory Board Member | 1.5yrs | €271.00k | 0.026% $ 95.7k | |
| Chairman of the Board of Directors & Chairman of Scientific Advisory Board | 4.3yrs | €132.00k | 0.060% $ 222.2k | |
| Member of the Board of Directors | 5.8yrs | €127.00k | 0% $ 0 | |
| Supervisory Board Member & Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Member Scientific Advisory Board | 6.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.5yrs | sin datos | sin datos | |
| Member of the Board of Directors | 1.8yrs | €84.00k | 0% $ 0 |
6.2yrs
Permanencia media
63.5yo
Promedio de edad
Junta con experiencia: La junta directiva de PRQR se considera experimentada (6.2 años de antigüedad promedio).